(original) (raw)

TY - JOUR AU - De Bernardi, B. AU - Mosseri, V. AU - Rubie, H. AU - Castel, V. AU - Foot, A. AU - Ladenstein, R. AU - Laureys, G. AU - Beck-Popovic, M. AU - de Lacerda, A F AU - Pearson, A D J AU - De Kraker, J. AU - Ambros, P F AU - de Rycke, Y. AU - Conte, M. AU - Bruzzi, P. AU - Michon, J. PY - 2008 DA - 2008/10/01 TI - Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group JO - British Journal of Cancer SP - 1027 EP - 1033 VL - 99 IS - 7 AB - Main objective of this study was to confirm that surgery alone is an effective and safe treatment for localised resectable neuroblastoma except stage 2 with amplified MYCN gene (MYCNA). Of 427 eligible stages 1–2 patients, 411 had normal MYCN and 16 had MYCNA. Of the 288 stage 1 patients with normal MYCN, 1 died of complications and 16 relapsed, 2 of whom died; 5-year relapse-free survival (RFS) and overall survival (OS) rates were 94.3% (95% confidence interval (CI): 91.6–97) and 98.9% (95% CI: 97.7–100), respectively. Of the 123 stage 2 patients with normal MYCN, 1 died of sepsis and 22 relapsed, 8 of whom died (RFS 82.8%, 95% CI: 76.2–89.5; OS 93.2%, 95% CI: 88.7–97.8). In stage 2, OS and RFS were worse for patients with elevated LDH and unfavourable histopathology. Of 16 children with MYCNA, 7 were stage 1 (5 relapses and 4 deaths) and 9 were stage 2 (3 relapses and 2 deaths) patients. In conclusion, surgery alone yielded excellent OS for both stage 1 and 2 neuroblastoma without MYCNA, although stage 2 patients with unfavourable histopathology and elevated LDH suffered a high number of relapses. Both stage 1 and 2 patients with MYCNA were at greater risk of relapse. SN - 1532-1827 UR - https://doi.org/10.1038/sj.bjc.6604640 DO - 10.1038/sj.bjc.6604640 ID - De Bernardi2008 ER -